Date: 2014-04-28
Type of information: Grant
Company: SYMPATH consortium (AFFiRiS AG (Austria), Biolution GmbH (Austria), University Hospital Bordeaux (France), INSERM F-CRIN Toulouse (France), Prosenex Ambulatorium Betriebs-GmbH (Austria), Medical University Innsbruck, Department of Neurology (Austria), Forschungszentrum Jülich GmbH (Germany),University Hospital Toulouse (France) )
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: € 6 million
Funding type: grant
Planned used: The SYMPATH consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates (PD01A and PD03A) in parallel for Parkinson\'s Disease (PD) and Multiple System Atrophy (MSA). Both candidates target a protein called alpha-synuclein, which plays a key role in the onset and progression of PD and MSA. Additionally, the group attempts to identify biomarkers with diagnostic and prognostic value. Altogether, the consortium exerts medical and scientific key opinion leaders from Germany, France and Austria. The SYMPATH project especially focuses on an outstanding, innovative approach to the clinical testing of the two candidate vaccines based on Affiris\' Affitome®-technology,. Using a novel tandem strategy, the consortium will concomitantly evaluate the safety and explore the activity of both vaccine candidates in clinical phase I studies for both indications, PD and MSA. In addition to this tandem strategy, the SYMPATH consortium aims to identify biomarkers with diagnostic and prognostic value for both, PD and MSA. Furthermore, it will test the viability of using MSA as a clinical reference indication for synucleinopathies, a group of diseases characterized by the aggregation of alpha-synuclein into so called Lewy Bodies.
Others: * On April 28, 2014, the SYMPATH consortium has received EU funding for the development of therapeutic vaccines against Parkinson\'s Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS, the consortium has been awarded € 6 million. for advancing the clinical development of two therapeutic vaccines for the treatment of both Parkinson\'s Disease (PD) and Multiple System Atrophy (MSA). The vaccine candidates (PD01A and PD03A) form part of the development pipeline of the Austrian biotech company AFFIRIS AG that leads the consortium and the clinical development in the field.
Therapeutic area: Neurodegenerative diseases
